Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

PURPOSE: The high expense of newer, more effective adjuvant endocrine therapy agents (aromatase inhibitors [AIs]) for postmenopausal breast cancer contributes to socioeconomic disparities in breast cancer outcomes. This study compares endocrine therapy costs for breast cancer patients during the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Nattinger, Ann Butler, Pezzin, Liliana E, McGinley, Emily L, Charlson, John A, Yen, Tina W F, Neuner, Joan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320689/
https://www.ncbi.nlm.nih.gov/pubmed/25674506
http://dx.doi.org/10.1186/s40064-015-0827-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320689/
https://www.ncbi.nlm.nih.gov/pubmed/25674506
http://dx.doi.org/10.1186/s40064-015-0827-8

Ejemplares similares